
Artificial intelligence delivers meaningful value in drug development only when it is grounded in real-world constraints and tightly integrated into expert-led workflows, rather than treated as a standalone, model-first solution.
Andrew Lewis, PhD, is Chief Scientific Officer of Quotient Sciences.

Artificial intelligence delivers meaningful value in drug development only when it is grounded in real-world constraints and tightly integrated into expert-led workflows, rather than treated as a standalone, model-first solution.